BRD4 and nut midline carcinoma: This property grants the drug with the capacity to abrogate cell proliferation in vitro and to inhibit tumor growth in mice xenografted with a panel of cell lines bearing different BRD4–NUT translocations, thus suggesting a therapeutic potential for the treatment of NUT midline carcinoma (NMC) [61].